This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pacific Biosciences (PACB) Up 73.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
Pacific Biosciences Offers Insights on Aedes aegypti Genome
by Zacks Equity Research
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
by Zacks Equity Research
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -18.75% and -17.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences Introduces Enhancements to Sequel System
by Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
by Zacks Equity Research
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%
by Zacks Equity Research
Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Is the Options Market Predicting a Spike in Pacific Biosciences (PACB) Stock?
by Zacks Equity Research
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.
Pacific Biosciences (PACB) Loss In Line With Estimates in Q2
by Zacks Equity Research
Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -8.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
Moving Average Crossover Alert: Pacific Biosciences of California (PACB)
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB) is looking like an interesting pick from a technical perspective
Genomics Market Gains Momentum: 3 DNA Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
Pacific Biosciences to Gain From New Genome Sequencing Tools
by Zacks Equity Research
Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.
Why Is Pacific Biosciences (PACB) Down 6.7% Since its Last Earnings Report?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Loss Wider Than Expected in Q1
by Zacks Equity Research
Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.
Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?
by Zacks Equity Research
Pacific Biosciences gains ground on solid Sequel Growth, while shrinking service revenues raise concern.
Pacific Biosciences Gains as HudsonAlpha Picks Sequel System
by Zacks Equity Research
Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.
Pacific Biosciences Unveils New Version of Sequel Software
by Zacks Equity Research
Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.
Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?
by Zacks Equity Research
Surging implied volatility makes Pacific Biosciences (PACB) stock lucrative to the option traders.